Literature DB >> 16436641

Specific detection of cytokeratin 20-positive cells in blood of colorectal and breast cancer patients by a high sensitivity real-time reverse transcriptase-polymerase chain reaction method.

Giuliana Giribaldi1, Simone Procida, Daniela Ulliers, Franca Mannu, Roberta Volpatto, Giorgia Mandili, Laura Fanchini, Oscar Bertetto, Gianruggero Fronda, Luigi Simula, Elena Rimini, Giovanni Cherchi, Lisa Bonello, Milena Maria Maule, Francesco Turrini.   

Abstract

A real-time reverse transcriptase-polymerase chain reaction (RT-PCR) method for detection of cytokeratin 20-positive cells in blood characterized by two novel features was developed and tested on 99 patients with colorectal cancer, 110 with breast cancer, and 150 healthy subjects. To optimize the specificity and sensitivity of the method, two novel features were used. First, a primer overlapping two adjacent exons was generated to inhibit nonspecific amplification both in healthy donors and cancer patients; second, a non-end-point first-round amplification was used to increase sensitivity. The number of first-round cycles was chosen to reach the highest level of sensitivity while conserving quantitative characteristics. PCR efficiency increased from 88.9% in single-round RT-PCR to 99.0% in nested real-time RT-PCR. To establish sensitivity and specificity of the method, HT29 cells were serially diluted with normal blood. Detection limit improved from 100 HT29 cells (single-round RT-PCR) to 1 to 10 cells (nested real-time RT-PCR) per 3 ml of whole blood. None of the healthy subjects was positive, whereas 22 and 29% of all colorectal and breast cancer patients, respectively, had cytokeratin 20 cell equivalents in blood. The association between cytokeratin 20 cell equivalents and metastasis was statistically significant for breast (P = 0.026) but not colorectal cancer patients (P = 0.361). Negativity of all 150 healthy controls examined confers diagnostic potential to the method.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16436641      PMCID: PMC1867572          DOI: 10.2353/jmoldx.2006.050054

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  47 in total

Review 1.  Molecular pathology of colorectal cancer.

Authors:  F T Bosman
Journal:  Cytogenet Cell Genet       Date:  1999

2.  Dissemination of tumor cells in patients undergoing surgery for colorectal cancer.

Authors:  J Weitz; P Kienle; J Lacroix; F Willeke; A Benner; T Lehnert; C Herfarth; M von Knebel Doeberitz
Journal:  Clin Cancer Res       Date:  1998-02       Impact factor: 12.531

3.  CK20 gene expression: technical limits for the detection of circulating tumor cells.

Authors:  P Champelovier; F Mongelard; D Seigneurin
Journal:  Anticancer Res       Date:  1999 May-Jun       Impact factor: 2.480

4.  Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients.

Authors:  P J Bostick; S Chatterjee; D D Chi; K T Huynh; A E Giuliano; R Cote; D S Hoon
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

5.  Quantitative real-time RT-PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers.

Authors:  Ronny Schuster; Nicole Max; Benno Mann; Karin Heufelder; Florian Thilo; Jörn Gröne; Franziska Rokos; Heinz-Johannes Buhr; Eckhard Thiel; Ulrich Keilholz
Journal:  Int J Cancer       Date:  2004-01-10       Impact factor: 7.396

6.  Detection of colorectal cancer cells in peripheral blood by reverse-transcriptase polymerase chain reaction for cytokeratin 20.

Authors:  D K Wyld; P Selby; T J Perren; S K Jonas; T G Allen-Mersh; J Wheeldon; S A Burchill
Journal:  Int J Cancer       Date:  1998-06-19       Impact factor: 7.396

7.  Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group.

Authors:  R M Goldberg; T R Fleming; C M Tangen; C G Moertel; J S Macdonald; D G Haller; J A Laurie
Journal:  Ann Intern Med       Date:  1998-07-01       Impact factor: 25.391

8.  Limitations of the reverse transcription-polymerase chain reaction method for the detection of carcinoembryonic antigen-positive tumor cells in peripheral blood.

Authors:  Y Ko; M Klinz; G Totzke; I Gouni-Berthold; A Sachinidis; H Vetter
Journal:  Clin Cancer Res       Date:  1998-09       Impact factor: 12.531

9.  Micrometastases and survival in stage II colorectal cancer.

Authors:  G J Liefers; A M Cleton-Jansen; C J van de Velde; J Hermans; J H van Krieken; C J Cornelisse; R A Tollenaar
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

10.  Detection of epithelial cancer cells in peripheral blood by reverse transcriptase-polymerase chain reaction.

Authors:  S A Burchill; M F Bradbury; K Pittman; J Southgate; B Smith; P Selby
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

View more
  8 in total

Review 1.  Serum tests for colorectal cancer screening.

Authors:  James Creeden; Frank Junker; Sabine Vogel-Ziebolz; Douglas Rex
Journal:  Mol Diagn Ther       Date:  2011-06-01       Impact factor: 4.074

2.  Quantitative real-time RT-PCR detection for CEA, CK20 and CK19 mRNA in peripheral blood of colorectal cancer patients.

Authors:  Dong Xu; Xu-fen Li; Shu Zheng; Wen-zhi Jiang
Journal:  J Zhejiang Univ Sci B       Date:  2006-06       Impact factor: 3.066

3.  Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients.

Authors:  Aikaterini Tsouma; Chrysanthi Aggeli; Panagiotis Lembessis; George-N Zografos; Dimitris-P Korkolis; Dimitrios Pectasides; Maria Skondra; Nikolaos Pissimissis; Anastasia Tzonou; Michael Koutsilieris
Journal:  World J Gastroenterol       Date:  2010-12-21       Impact factor: 5.742

4.  Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437.

Authors:  Monica M Reinholz; Kathleen A Kitzmann; Kathleen Tenner; David Hillman; Amylou C Dueck; Timothy J Hobday; Donald W Northfelt; Alvaro Moreno-Aspitia; Vivek Roy; Betsy LaPlant; Jake B Allred; Philip J Stella; Wilma L Lingle; Edith A Perez
Journal:  Clin Cancer Res       Date:  2011-10-05       Impact factor: 12.531

Review 5.  Molecular biomarkers for the detection of metastatic colorectal cancer cells.

Authors:  Hidenori Kamiyama; Hiroshi Noda; Fumio Konishi; Toshiki Rikiyama
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

6.  Circulating Tumor Cells Detected by RT-PCR for CK-20 before Surgery Indicate Worse Prognostic Impact in Triple-Negative and HER2 Subtype Breast Cancer.

Authors:  Seong Bae Hwang; Jeoung Won Bae; Hye Yoon Lee; Hoon Yub Kim
Journal:  J Breast Cancer       Date:  2012-03-28       Impact factor: 3.588

7.  Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients.

Authors:  S C C Wong; S S M Ng; M T Cheung; L Y Luk; C M L Chan; A H K Cheung; V H M Lee; P B S Lai; B B Y Ma; E P Hui; M Y Y Lam; T C C Au; A T C Chan
Journal:  Br J Cancer       Date:  2011-03-01       Impact factor: 7.640

8.  Microarray-based identification and RT-PCR test screening for epithelial-specific mRNAs in peripheral blood of patients with colon cancer.

Authors:  Rossella Solmi; Giampaolo Ugolini; Giancarlo Rosati; Simone Zanotti; Mattia Lauriola; Isacco Montroni; Marco del Governatore; Antonello Caira; Mario Taffurelli; Donatella Santini; Domenico Coppola; Lia Guidotti; Paolo Carinci; Pierluigi Strippoli
Journal:  BMC Cancer       Date:  2006-10-20       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.